Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2025-01555 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| HUM00257753 | Other Identifier | University of Michigan Comprehensive Cancer Center | |
| R01CA289631 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Observational | Patients receive standard care Pluvicto and undergo Lu-177 SPECT/CT scans on study. Patients may also undergo optional 99mTc-SC SPECT/CT scan for bone marrow dosimetry prior to cycle 1. In addition, patients have their medical records reviewed on study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-Interventional Study | Other | Non-interventional study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Response and toxicity following 177Lu-RLT | Association between absorbed dose and effect (response/toxicity) following 177Lu-RLT | Up to 4 years |
| Measure | Description | Time Frame |
|---|---|---|
| Build and test models | Build and test models for predicting therapy delivered absorbed dose from pre-therapy PET imaging/non-imaging biomarkers. | Up to 4 years |
Not provided
Inclusion Criteria:
* 177Lu-617 PSMA treatment scheduled for mCRPC
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with mCRPC undergoing 177Lu-PSMA-617 treatment at the University of Michigan
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yuni K Dewaraja | University of Michigan Rogel Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Michigan Comprehensive Cancer Center | Recruiting | Ann Arbor | Michigan | 48109 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |